In a study sponsored by Humacyte (Morrisville, NC), researchers from Duke University, 
East Carolina University, Yale University, and Humacyte have shown some promising results with tissue-engineered vascular grafts (TEVGs). TEVGs are bioengineered veins that can be used for coronary artery bypass graft surgery and vascular access for hemodialysis. The veins, with a diameter of 3 to 6 mm, were generated in a bioreactor using human and canine smooth muscle cells, decellularized, and stored up to 12 months in refrigerated conditions. After that the veins were implanted in nine adult male baboons and five mongrel dogs. They showed excellent blood flow and resistance to dilatation, calcification and intimal hyperplasia, meaning less chance of occlusion. With this technique, patients who do not have suitable veins of their own could be helped with donor material. One donor could produce grafts for multiple patients. Being tested on animals, this is still in early development, but the results are hopeful. Results were published in the journal Science Translational Medicine.
Press release: Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis…
Article abstract: Readily Available Tissue-Engineered Vascular Grafts…